RecruitingEarly Phase 1NCT07007078

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Acne Vulgaris


Sponsor

Shanghai Zhongshan Hospital

Enrollment

60 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is: • Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris. Participants will: * Take DHA every day for 3 months * Visit the clinic once every month for checkups and tests


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria2

  • Clinically diagnosed with acne vulgaris;
  • For female patients, no pregnancy plans within the next 6 months.

Exclusion Criteria4

  • Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;
  • Patients who have used topical medications for acne within the past 2 weeks;
  • Pregnant or breastfeeding women;
  • Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdihydroartemisinin

DHA 40mg tid for 90 days


Locations(1)

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07007078


Related Trials